How Pharma Price Gouging Has Left Americans in a Helpless State

PUBLISHED BY
Christy Gren



TAGS:


2 years ago




“Americans pay the highest drug prices in the world because pharma companies need the bounty for Research and Development.” We often come across this narrative put across by pharma lobbyists to justify pharma price gouging. American pharma companies spent billions of dollars on R&D and this effort in creating new drugs has certainly helped the world in many ways. But does that justify the high prices Americans are paying for some important, life-saving drugs? The high profits that some pharma companies are earning, how much of it is actually used for research?

Consider the example of Turing pharmaceuticals that acquired the drug Daraprim, a drug used in treating an illness associated with AIDS, when its patent had expired. Generally, once the patent of a new drug expires, generic variants enter and are sold in the market at low prices. Since the R&D costs and production costs of companies producing such generic drugs are low, they are able to sell them to the public at low prices.  Turing seized the day and acquired Daraprim at a time when there were no generic variants available. But, instead of lowering the cost or even keeping it unchanged, Turing hiked the price by more than forty-folds. The price of Daraprim increased from $13.50 to $750, practically overnight.

 

 

“Is this price manipulation even legal?” one might ask. It is!

The US follows a free market system of pricing for pharmaceutical products. Pharma companies are free to price their drugs however they want and that is exactly what they do. Daraprim isn’t the only example. Recently, we have seen several instances of pharma price gouging. After Valeant Pharma acquired Isuprel and Nitropress from Marathon Pharma, Valeant increased their prices by 525 percent and 212 percent respectively.

The public is both at the beginning and the end of the funnel. They pay high prices to buy these drugs and they also pay for creating these drugs. These Pharma companies often acquire drugs created as a result of NIH- funded university research. Furthermore, American pharma companies can take a tax write-off on their direct-to-consumer advertising. So, while the burden of high prices and research funding is carried by the general public, big pharma companies enjoy massive profits. According to a report by Axios, while pharma companies bring in 23 percent of health care’s US revenues, they make 63 percent of the total profits. Since such companies have monopolies over these vital drugs, pharma price gouging leaves the public in an “it’s either pay or suffer” situation.

When contested, these pharma companies often hide behind the same narrative – “profits from high prices are required to fund Research & Development.” But in reality, these pharma companies seldom introduce any ground-breaking drugs instead, they introduce “follow-on” drugs. Follow-on drugs are the drugs which are very similar to the existing drugs but are marketing with new names, labels and with a claim of having a better therapeutic action. While some follow-on drugs are regarded by the FDA as having some improvement, 67 percent are conferred as having no significant benefit. The term “me-too drugs” that is often attributed to such follow-on drugs, thus, seems to be very apt.

Avatar
Christy Gren
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine she enjoys writing about Unicorns, Silicon Valley, Startups, Business Leaders and Innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B.

Recent Posts

Germany to pay Vatenfall, RWE, EnBw and E.ON for premature closure of nuclear plans

Germany to pay Vatenfall, RWE, EnBw and E.ON for premature closure of nuclear plans

The German government is paying out billions of euros to energy companies EON, EnBW, RWE and Vatenfall in compensation for the closure of th...
6 hours ago
Bank of America makes a windfall in trading revenue during Texas blackout

Bank of America makes a windfall in trading revenue during Texas blackout

The Texas electric grid failure in the severe winter storms last month brought a windfall for the Bank of America in hundreds of millions of...
7 hours ago
Credit Suisse withdraws $10 billion from Greensill

Credit Suisse withdraws $10 billion from Greensill

Greensill Capital, a provider of supply-chain financing, is facing further trouble with Credit Suisse, the Swiss bank, withdrawing $10bn of ...
3 days ago
Melrose plans to divest Nortek for $3.5 billion

Melrose plans to divest Nortek for $3.5 billion

Melrose Industries Plc, the UK buyout specialist, plans to divest its US-based Nortek division that makes heating and air conditioning produ...
3 days ago
Honda to Sell Limited Level 3 Autonomous Driving Legend Sedan

Honda to Sell Limited Level 3 Autonomous Driving Legend Sedan

Honda Motor Co Ltd plans to sell 100 of its flagship Legend sedan packed with its Sensing Elite autonomous driving features with level 3 aut...
4 days ago
U.S. Airline Industry Desperate for Next Round of Stimulus

U.S. Airline Industry Desperate for Next Round of Stimulus

Another $15 billion in bailout funds is being considered for the hard-pressed U.S. airline industry by the US Congress, bringing a much-need...
4 days ago